Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026
18/08/2026 11:41
BRIEF-Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026 Aug 18 (Reuters) - Shilpa Medicare Ltd SHME.NS:
SHILPA MEDICARE - INITIATES VOLUNTARY RECALL OF 27,923 PEMETREXED INJECTION VIALS IN US ON JULY 29, 2026
SHILPA MEDICARE - RECALL COVERS 4 BATCHES DUE TO ATYPICAL DISCOLORATION OF DRUG PRODUCT
SHILPA MEDICARE - US FDA CLASSIFIES RECALL AS CLASS II (HOSPITAL LEVEL)
SHILPA MEDICARE - RECALL DOES NOT AFFECT OTHER PRODUCTS OR SUPPLY
SHILPA MEDICARE - NO ADVERSE EVENT REPORTED FOR AFFECTED BATCHES
SHILPA MEDICARE - COMPANY DOES NOT FORESEE MATERIAL IMPACT OF RECALL ON FINANCIAL POSITION OR OPERATIONS
Source text: ID:nBSE2zBQ4q
Further company coverage: SHME.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026